Clinical TrialID 7365
Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis
NCT05520944
COVID-19|COVID-19 Pandemic|COVID-19 Respiratory Infection|SARS CoV 2 Infection|SARS-CoV-2 Acute Respiratory Disease
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 7365
- Evidence Id
- 7365
- Core Evidence Id
- 7365
- Source Clinical Trial Id
- 7359
- Herb2 Clinical Trial Id
- HBCT007359
- Nct Id
- NCT05520944
- Title
- Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis
- Status
- Phase
- Study Result
- No
- Study Condition
- COVID-19|COVID-19 Pandemic|COVID-19 Respiratory Infection|SARS CoV 2 Infection|SARS-CoV-2 Acute Respiratory Disease
- Study Type
- Observational
- Study Design
- Observational Model: |Time Perspective: p
- Intervention
- DRUG: ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray
- Intervention Allocation
- Intervention Model
- Intervention Mask
- Intervention Purpose
- Gender
- All
- Age
- Child, Adult, Older_Adult
- Enrollment
- 1000
- Outcome Measure
- Time to Clinical Recovery, Defined as the change from baseline to end of treatment in COVID-19 symptoms on a 10-item ordinal scale\* ("A minimal common outcome measure set for COVID-19 clinical research," 2020)., Baseline through Day 10-End of Treatment|Incidence of significant COVID-19-related clinical events, Such as anosmia, dysgeusia, cough, and nasal congestion., Baseline through Day 10-End of Treatment|Incidence and severity of serious adverse events (SAEs), Baseline through Day 10-End of Treatment|Incidence and severity of adverse events (AEs) of interest, Such as irritation in the nasal fossa, Headache, Epistaxis, modification or discontinuation, Baseline through Day 10-End of Treatment|treatment period in the incidence of hospitalizations, Baseline through Day 10-End of Treatment
- Sponsor Collaborator
- Dr. Ferrer BioPharma|Clinica Union Medica Del Norte, S.A.S., Santiago, República Dominicana
- Funded By
- INDUSTRY
- Location
- Clinica Union Medica, Santiago De Los Caballeros, Dominican Republic
- Other Id
- DFB-004
- Start Date
- 2021-08-26
- Primary Completion Date
- 2022-09-30
- Completion Date
- 2022-10-01
- First Posted
- 2022-08-30
- Results First Posted
- Last Update Posted
- 2022-08-30
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT05520944
- Title Cn
- Title En
- Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis
- Bilingual Status
- semi_complete